Glaucoma Medication Manufacturers
A number of medications are currently in use to treat glaucoma.
Menu
Menu
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
A number of medications are currently in use to treat glaucoma.
When Glaucoma Research Foundation first launched Catalyst for a Cure in 2002, our bold idea was to recruit the most promising young researchers from different fields to work collaboratively.
Pilot project grants support new and promising ideas in the field of glaucoma research.
Some people may have early warning signs, but most patients will not notice any vision loss until the disease is at a late stage.
It’s almost summertime again and for many people this means travel, warm weather and outdoor activities. For those with glaucoma, the summer season can present new challenges.
“At Glaucoma Research Foundation, we share your sense of urgency to do all we can to speed the pace of discovery for a cure for glaucoma.” — Thomas M. Brunner, President and CEO
“There is no question: We are moving closer to the goal line — a cure for glaucoma.” – Bob Stamper, MD
The Glaucoma Research Foundation in San Francisco joins eye health organizations and eye care professionals worldwide for World Glaucoma Week each year in March.
A number of factors affect the decision of whether to surgically remove cataracts in the patient with glaucoma.
Patients with glaucoma want to help themselves and save their sight in any way they can beyond medications and surgery.
There are two main types of glaucoma, primary open-angle and primary angle-closure, each with very different features.
Xin Duan, PhD is an Assistant Professor of Ophthalmology at the UC San Francisco Weill Institute of Neuroscience, where in 2017 he received a Trailblazer Award in Neuroscience.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2022 all rights reserved.
Print Subscription
(The printed edition of the Gleams newsletter is only available if you live in the United States or Canada)
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.